Thursday, July 9, 2026
🇺🇸 FDA

biotech · PIK3CA Mutation · PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation · RLAY

Relay Therapeutics

Relay Therapeutics patent portfolio — 12 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Cambridge, USA HQ
2016 Founded
211 Employees
Public company Type
RLAY · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2016
Employees
211
Programs
6
Drugs
7
Patents
12
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Relay Therapeutics patents

12 pharmaceutical patents indexed for Relay Therapeutics. 0 expire within 24 months.

Relay Therapeutics has 12 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

12 patents

Patent portfolio

  1. US 12331056

    SHP2 phosphatase inhibitors and methods of use thereof

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12219327

    Substituted isoindolines as PI3K-alpha inhibitors

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12152034

    FGFR inhibitors and methods of making and using the same

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12138263

    Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12084447

    SHP2 phosphatase inhibitors and methods of use thereof

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11890281

    SHP2 phosphatase inhibitors and methods of making and using the same

    Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11780845

    FGFR inhibitors and methods of use thereof

    Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11701354

    Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11629145

    SHP2 phosphatase inhibitors and methods of use thereof

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11591336

    Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11529347

    SHP2 phosphatase inhibitors and methods of use thereof

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10934302

    SHP2 phosphatase inhibitors and methods of use thereof

    Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Relay Therapeutics have?

12 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Relay Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.